Hence, these findings confirmed that CDK4 inhibition, triggered by palbociclib, could decrease synovial sarcoma cell proliferation and growth via induction of cell apoptosis via arresting the cell cycle in G1 phase. The gene discussed is CDK4; the disease is synovial sarcoma.